Remove 2028 Remove FDA Remove Licensing
article thumbnail

From Discretion to Regulation: What FDA’s Final Rule Means for Laboratory Developed Tests

Hall Render

In April 2024, the Food and Drug Administration (“FDA”) issued a Final Rule amending the definition of in vitro diagnostics products (“IVDs”) found in 21 C.F.R. Stage 3: Effective May 6, 2027 Three years after the Final Rule’s publication, the FDA will enforce all remaining quality system requirements (under 21 C.F.R.

FDA 40
article thumbnail

Healthcare Reforms Under the IRA: Expanding Access to Care

Healthcare Law Blog

Fifteen more Part D drugs are set to be published in 2027, followed by 15 Part D and Part B drugs, collectively, in 2028. Drugs eligible for negotiation must be FDA-approved for at least 7 years and marketed in conformance with the Federal Food, Drug, and Cosmetic Act. Negotiation-Eligible Drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – March And April

SQA

The company did not have a written procedure in place for the provision of information related to serious risk of injury to health, contrary to what was committed to on it establishment license application. The name and address of manufacturers provided by the company on its establishment license application were not accurate.

FDA 40
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – January

SQA

Of interest is a reference to the FDA’s draft document “Computer Software Assurance for Production and Quality System Software,” which was recently published on 13 September 2022. PCPC looks forward to working with the FDA and key stakeholders to implement this important legislation.

article thumbnail

SQA Regulatory Surveillance Summary for May and June 2024

SQA

Most synthetic injectable peptides are regulated as prescription drugs in Canada and require a prescription from a licensed healthcare professional. The deadline to submit feedback for this plan is 25 July 2024. is recalling one lot of ratio-ECTOSONE (TEVA-ECTOSONE) 0.05% mild lotion in 60 mL bottles.

FDA 52
article thumbnail

Health Provider News

Hall Render

Nursing assistant’s license suspended after arrest, inappropriate relationship with patient R.I. drug developers.

article thumbnail

Health Provider News – March 11, 2022

Hall Render

FDA final guidance presses industry to be ‘recall ready’ Final vaccine mandate deadlines still in play, despite removal vote. Nurses are waiting months for licenses as hospital staffing shortages spread. Nurses are waiting months for licenses as hospital staffing shortages spread. in capital projects by 2028.